Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Breast Cancer treatment details. Biologic therapy. Chemotherapy. Indiana, University, Indianapolis, IN, United States

Survival: 15.1 months
Toxicity Grade: 4
Treatments: Biologic therapy
Drugs: Xeloda
Country: United States
City/State/Province: Indianapolis, IN
Hospital: Indiana, University
Journal: Link
Date: 2/2005

Patients: This Phase III study involved 462 women with metastatic breast cancer. The patients were randomly divided into two groups. In Group B, there were 232 patients (mean age 51).

Treatment: The treatment for Group B consisted of capecitabine (chemotherapy) and bevacizumab (monoclonal antibody).

Toxicity: In Group B, Grade 3-4 toxicities included hypertension, thrombosis, hand-foot syndrome, diarrhea, stomatitis, asthenia, leukopenia, and nausea.

Results: The median overall survival for Group B was 15.1 months. The authors concluded, "the addition of bevacizumab to capecitabine produced a significant increase in response rates, this did not translate into improved PFS or overall survival."

Support: Genentech financially supported this study, and several authors were employed by and have financial interests in Genentech. Genentech manufactures and markets bevacizumab.

Correspondence: Kathy D. Miller, M.D.

E-mail to a Friend Email Physician More Information